WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript

Yang Huang
JPMorgan Chase & Co, Research Division

Okay. I think we can get started. Good evening, good afternoon, good morning, depending on where you are. Welcome. This is Yang, China Healthcare Analyst at JPMorgan. It is my pleasure to host the WuXi Biologics 2026 Interim Results Conference Call.

WuXi Bio just reported a very strong first half with revenue up 18.4% year-over-year and total backlog increased by 30% year-over-year, and the gross margin also expanded to 46.2%. So we are expecting company give us more color on their strong first half.

Joining us today are Dr. Chris Chen, CEO; Mr. Ming Tu, CFO; and Dr. Lina Fan, Head of IR.

Following prepared remarks, we will move to a Q&A session. [Operator Instructions]

Now I’ll turn the call over to WuXi Bio management team.

Chris Chen
CEO & Executive Director

Thank you, Yang. Good morning, good afternoon, good evening, global investors. The panel of our talk is innovation, execution and global scale driving sustainable high growth. I think I want to highlight all 3 aspects: innovation, our innovation on multi-specifics or ADCs, our execution, our speed to deliver projects, our quality, and we can quickly scale from 200 projects to 300 projects for our M programs and the global scale. We see more and more manufacturing coming to our site in global, in Ireland, in Germany, in U.S. So our dual site using China to launch the product and then have our global site as a backup as a secondary supplier now really works for our global clients.